Damora Therapeutics, Inc. (DMRA) Stock Ticker
DMRA right now
Market factors today
Unlock the full DMRA picture
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
DMRA stock facts
| Ticker symbol | DMRA |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.3B |
| CEO | Jennifer A. Jarrett |
| Employees | 7 |
| Headquarters | Waltham, MA, US |
| IPO date | 2020-10-29 |
| Website | www.damoratx.com |
What you can see for DMRA on Tickr
Live DMRA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the DMRA report.
Rankings
FAQ
What is the ticker symbol for Damora Therapeutics, Inc.?
The ticker symbol for Damora Therapeutics, Inc. is DMRA, listed on the NASDAQ Capital Market.
What is DMRA?
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to…